MedWatch

The pharma industry after two years with the Medicines Council: Still need for changes

Despite two years of existence, the Danish Medicines Council is still challenged, especially in ensuring shorter review time and quicker access to therapies. This is according to the pharma industry that calls for change.

Foto: Kristian Brasen/Ritzau Scanpix

These days, the Danish Medicines Council can celebrate its second birthday.

The national priority-setting body still enjoys support from the pharma industry, but several drug groups also stress the need for adjustments of the council's work that has often caused unnecessary delays of drug reviews, exceeding the 12 weeks time-limit.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier